Association of genetic variations in ACE2, TIRAP and factor X with outcomes in COVID-19.

BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can manifest with varying disease severity and mortality. Genetic predisposition influences the clinical course of infectious diseases. We investigated whether genetic polymorphisms in candidate genes ACE2, TIRAP, and factor X are associated with clinical outcomes in COVID-19.
METHODS: We conducted a single-centre retrospective cohort study. All patients who visited the emergency department with SARS-CoV-2 infection proven by polymerase chain reaction were included. Single nucleotide polymorphisms in ACE2 (rs2285666), TIRAP (rs8177374) and factor X (rs3211783) were assessed. The outcomes were mortality, respiratory failure and venous thromboembolism. Respiratory failure was defined as the necessity of >5 litres/minute oxygen, high flow nasal oxygen suppletion or mechanical ventilation.
RESULTS: Between March and April 2020, 116 patients (35% female, median age 65 [inter quartile range 55-75] years) were included and treated according to the then applicable guidelines. Sixteen patients (14%) died, 44 patients (38%) had respiratory failure of whom 23 required endotracheal intubation for mechanical ventilation, and 20 patients (17%) developed venous thromboembolism. The percentage of TIRAP polymorphism carriers in the survivor group was 28% as compared to 0% in the non-survivor group (p = 0.01, Bonferroni corrected p = 0.02). Genotype distribution of ACE2 and factor X did not differ between survivors and non-survivors.
CONCLUSION: This study shows that carriage of TIRAP polymorphism rs8177374 could be associated with a significantly lower mortality in COVID-19. This TIRAP polymorphism may be an important predictor in the outcome of COVID-19.

Introduction

The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since December 2019, the virus quickly spread around the world and the World Health Organization reported more than 182 million patients as of June 2021 [1]. COVID-19 is associated with a heterogeneous clinical course, varying from asymptomatic to severe disease requiring mechanical ventilation. Various (clinical) factors are associated with a more severe course of COVID-19, among which are male gender, older age, and comorbidities, such as hypertension, cardiovascular disease, diabetes mellitus, chronic lung disease and cancer [1, 2]. Diversity in the clinical course of COVID-19 may be related to differences in virulence among SARS-CoV-2 strains [3]. Genetic predisposition might influence disease course, as is seen in other respiratory viral infections, such as influenza and respiratory syncytial virus [4].

SARS-CoV-2 is member of the Coronaviridae family. The receptor-binding domain of the spike protein of SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptor which leads to membrane fusion and entry of SARS-CoV-2 into the target cells [5]. Differences in the function of ACE2 might influence susceptibility of COVID-19 [6]. After cellular entry of SARS-CoV-2, viral infection is likely sensed by the immune system through pattern recognition receptors, such as toll-like receptors (TLRs) that serve to recognise pathogens like coronaviruses [7]. Since SARS-CoV-2 is a single-stranded RNA virus, TLR7 seems likely to be implicated in the initial immune response to the virus [8]. TLRs are also able to detect endogenous ligands resulting in an inflammatory response. For example, oxidised phospholipids are agonists for TLR4 and stimulation of TLR4 was associated with acute respiratory distress syndrome in experimental mouse models for acute lung injury, and TLR4 promotes a strong cytokine release by human alveolar macrophages in vitro [9, 10]. Phospholipids present in alveolar surfactant are oxidised by neutrophil myeloperoxidase, reported to be at increased levels in COVID-19 patients [11-13]. Therefore, TLR4 and its subsequent downstream pathway may be of critical importance in SARS-CoV-2 induced acute respiratory distress syndrome and subsequent mortality, even though SARS-CoV-2 does not directly bind to TLR4. Upon stimulation, TLRs activate intracellular adaptor proteins and pro-inflammatory pathways are stimulated. TIRAP, also known as Mal, is a toll/interleukin-1 receptor domain-containing adaptor protein for TLR2 and TLR4. After stimulation, TIRAP recruits MyD88 and triggering the MyD88 transduction signalling pathway results in activation of nuclear factor-κB and the subsequent expression of pro-inflammatory cytokines, such as interleukin-1, interleukin-6 and tumour necrosis factor alpha [14]. depicts a schematic representation of this pathway. Pro-inflammatory cytokines are associated with a worse clinical outcome in COVID-19 [6, 15]. Interleukin-6 and tumour necrosis factor alpha are predictive in COVID-19 survival [16]. The rs8177374 polymorphism of TIRAP attenuates the function of TIRAP, leading to reduced production of pro-inflammatory cytokines [17, 18]. This polymorphism has been associated with an attenuated course of several infectious diseases, but has not been studied in relation to SARS-CoV-2 [17, 18].

Proposed simplified schematic representation of SARS-CoV-2 induced intracellular pro-inflammatory signalling pathway.

Abbreviations: IL; interleukin, MyD88; myeloid differentiation factor 88, NFkB; nuclear factor-kappa B, TIRAP; toll/interleukin-1 receptor domain-containing adaptor protein, TLR; toll-like receptor, TRAF6; TNF Receptor Associated Factor 6, TRIF; TIR-domain-containing adapter-inducing interferon-β, ssRNA; single-strand ribonucleic acid, dsRNA; double-strand ribonucleic acid.

COVID-19 is often complicated by thrombo-embolic events [19]. Coagulation and inflammation are related, suggesting that coagulation plays a role in COVID-19 [20]. Polymorphisms in coagulation factor X may be associated with infection related disorders [21]. A phenome-wide association study revealed that missense mutation rs3211783 was associated with various infections, including viral infections, but not with thrombo-embolic events [21]. Protease factor Xa cleaves the SARS virus S protein into S1 and S2 subunits when the virus enters the target cells, which increases infectivity [22].

Abnormalities in expression of substituents of TLR induced pro-inflammatory signalling pathways, such as TIRAP, or abnormalities in ACE2 or factor X may alter course of a SARS-CoV-2 infection. Single nucleotide polymorphisms (SNPs) in these genes may modify expression or affect the function of translated proteins. Variations in the function of these proteins might partially explain the heterogeneous clinical course of COVID-19. Therefore, we hypothesised that carriage of selected SNPs in candidate genes ACE2 (rs2285666), TIRAP (rs8177374), and factor X (rs3211783) are associated with the clinical course of SARS-CoV-2 infection.

Materials and methods

Study design

The Markers in COVID-19 And Relations to Outcomes in the Netherlands (MACARON) study was a single-centre retrospective cohort study. The study protocol was approved by the local Medical Ethical Committee (TWO 20–043).

Setting and study population

All patients with a clinical suspicion of SARS-CoV-2 infection who visited the emergency department of the Meander Medical Centre in Amersfoort, the Netherlands between 23 March and 20 April 2020 were enrolled in the study. Blood samples were obtained upon presentation at the emergency department. Adults of Western European descent with proven SARS-CoV-2 infection were eligible for SNP determination. A nasopharyngeal swab was obtained for the detection of SARS-CoV-2 by reverse-transcriptase polymerase chain reaction (PCR). Patients were followed during the entire period of hospitalisation until discharge and treated according to the Dutch guidelines in March and April 2020, which at that time included treatment with chloroquine for patients with respiratory failure [23]. Patients who visited the emergency department but were not hospitalised were assumed to have no respiratory failure or venous thrombo-embolism at time of consultation.

Data collection

Clinical data were collected using an electronic case report form based on a template of the World Health Organization [24]. Patient characteristics at baseline, symptoms on admission and outcomes were extracted from the electronic medical records. Comorbidities and use of co-medication were collected as present at the time of diagnosis of COVID-19. Pulmonary disease was defined as one of the following diseases: chronic obstructive pulmonary disease, asthma, interstitial lung disease, obstructive sleep apnoea or lung cancer. Auto-immune or inflammatory disease was defined as any rheumatologic disorder, inflammatory bowel disease or sarcoidosis. Malignant neoplasm was defined as a current or past solid organ or haematological malignancy (non-melanoma skin cancers excluded). Antithrombotic drugs were defined as therapy with an anti-platelet agent (acetylsalicylic acid, adenosine diphosphate receptor inhibitors or dipyridamole) or anticoagulants (direct oral anticoagulants or coumarins), or both.

Respiratory failure, venous thromboembolism and mortality were determined as the main outcome measures of the study. Respiratory failure was defined as the necessity of >5 liters/minute oxygen, high flow nasal oxygen suppletion or mechanical ventilation. Venous thromboembolism was defined as pulmonary embolism or deep vein thrombosis diagnosed by computed tomography angiography for pulmonary embolism or ultrasonography for deep vein thrombosis. Mortality was defined as in hospital mortality and within 14 days after palliative discharge.

DNA isolation and SNP determination

Routine blood tests were performed in the emergency department and plasma remnants were used for laboratory testing. Plasma was separated from blood according to local protocol and was subsequently stored at -70 degrees Celsius prior to DNA extraction. DNA was extracted from 200μl plasma with the fully automated QIASymphony system (Qiagen, Venlo, the Netherlands) using the DSP DNA Mini Kit (Qiagen), yielding 200μl eluate to be used for further processing. SNP databases were used to assess background incidence of the studied SNPs. The following SNPs were assessed and analysed for this study: ACE2 rs2285666, TIRAP rs8177374, factor X rs3211783. Carriage included both heterozygote and homozygote mutation carriers. For the ACE2 and TIRAP SNPs, real time PCRs with specific primer pairs and probes (Biolegio Lab Equipment B.V., Nijmegen, the Netherlands) were performed to determine the various alleles, see for primers and probes sequences. Genotyping was performed using the CFX96 system (Bio-Rad Laboratories Inc., California, United States of America) and analysed with Bio-Rad CFX manager 3.1. The total volume per sample was 20 microliter (5 μl DNA, 10 μL LightCycler probes master mix 2x (Roche Diagnostics Netherlands B.V., Almere, the Netherlands), 0.18 μl of both primers (stock concentration 100 μM dissolved in TE buffer), 0.27 μl of both probes (stock concentration 15 μM), 4.1 μl water (Roche Diagnostics Netherlands B.V., Almere, the Netherlands). PCR conditions were 2 minutes at 50°C, 10 minutes at 95°C, and 45 cycles of 10 seconds at 95°C and 1 minute at 60°C. The factor X SNP was ordered as Assay-On-Demand from Applied Biosystems (California, United States of America) and was determined according to manufacturers’ protocol on the Bio-Rad CFX system.

Statistical analysis

Continuous variables with non-normal distribution were presented as a median with an inter-quartile range (IQR). Categorical variables were expressed as counts and percentages.

Univariate analyses were performed with Fisher’s exact test to examine the association between SNP carriage and clinical outcomes. The Mann-Whitney U test was performed to compare biochemical parameters between different genotypes. A p-value of <0.05 was considered statistically significant. To correct for multiple testing, the Bonferroni correction was applied when appropriate. Analyses were performed using IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, N.Y., USA).

Results

Patient characteristics

Of 484 patients suspected of SARS-CoV-2 infection that visited the emergency department, 116 met inclusion criteria and underwent SNP analysis (). Patient characteristics are presented in . More than half (65%) were male and just over half (58%) had a body-mass index > 25 kg/m2. Hypertension was the most common comorbidity (37%). Median duration of symptoms prior to hospital admission was 8 days (IQR 5–12). Ninety patients (78%) were hospitalised of whom 66/90 (73%) were treated with oseltamivir and 43/90 (48%) were treated with chloroquine. Ten patients (11%) received intravenous prednisone. None of the patients received other antiviral or anti-inflammatory agents, such as tocilizumab or dexamethasone. Median length of hospital stay until discharge was 5 days (IQR 3–11 days). Of the 90 hospitalised patients, 28 patients (31%) had advanced directives excluding admission to the ICU for mechanical ventilation, if this situation would occur.

Outcomes

During the observation period of the study, 16/116 patients (14%) died of whom 13 patients on the ward, two patients on the Intensive Care Unit and one patient at home (two days after discharge). The mortality group was equal between sexes. Median age of patients that died was 75 years (IQR 71–83). Respiratory failure occurred in 44/116 patients (38%) of whom 23 required endotracheal intubation and mechanical ventilation at the intensive care unit. The remaining 21 patients with respiratory failure were treated with oxygen therapy: oxygen mask (n = 5), venturi mask (n = 2), non-rebreathing mask (n = 11) or high flow nasal oxygen suppletion (n = 3). Seventeen percent (20/116 patients) developed a venous thrombo-embolism: 17 patients had a pulmonary embolism, two patients had deep vein thrombosis, and one patient both.

Genotype distribution

The genotype distribution is shown in . Determination of the various alleles was successfully in 115 out of 116 patients. Determination of TIRAP polymorphism of one patient could not be determined due to technical issues. Genotype distribution for each clinical outcome is shown in Tables . shows the distribution of the clinical outcomes stratified per genotype. The percentage of TIRAP polymorphism carriers in the survivor group was 28% as compared to 0% in the non-survivor group (p = 0.01, Bonferroni corrected p = 0.02). The proportion of carriage of TIRAP polymorphism was also markedly higher in patients without respiratory failure, although not statistically significant. No obvious differences in distribution of the TIRAP polymorphism and the occurrence of venous thromboembolism were found. No significant differences were observed in genotype distribution for the ACE2 polymorphism and clinical outcome. None of the patients were carrier of the factor X polymorphism. shows levels of C-reactive protein, D-dimer and ferritin in patients with TIRAP carriage and TIRAP wild-type. Levels of these biochemical parameters show a similar distribution between the two genotype groups at the moment of presentation at the emergency department.

Discussion

In this study we investigated the potential association between genetic polymorphisms and clinical outcomes in COVID-19. Our findings demonstrated that carriage of the TIRAP polymorphism rs8177374 was significantly associated with lower mortality in COVID-19. To our knowledge, no other studies have investigated the association between this polymorphism in the TIRAP gene (rs8177374) and clinical outcomes in patients with SARS-CoV-2 infection. This TIRAP polymorphism may be associated with a lower risk for respiratory failure, though this finding did not reach statistical significance.

The allele frequency of TIRAP polymorphism rs8177374 ranges between 16–34% in the European population which accords to the frequency found in our study (24%) [25, 26]. Increased levels of several pro-inflammatory cytokines and immune hyperactivation are associated with a worse clinical outcome in COVID-19 [6, 15]. One could therefore speculate that decreased cytokine production due to the rs8177374 variant of TIRAP leads to a more beneficial clinical course. This TIRAP polymorphism could be of value in risk stratification for mortality in hospitalised patients. Furthermore, it may help to identify which patients will benefit from expensive treatment, such as tocilizumab, an anti-interleukin-6 receptor monoclonal antibody. We did not measure levels of cytokines such as interleukin-1 and interleukin-6 in the current study. However, we did measure downstream inflammatory markers such as C-reactive protein, D-dimer and ferritin. C-reactive protein is a surrogate for the interleukin-6 pathway [27]. The results show a similar distribution between patients with TIRAP carriage and TIRAP wild-type at the moment of presentation at the emergency department. However, this study was not designed to determine an association between the candidate genes and biochemical parameters. The patients in our study presented at different days of onset of SARS-CoV-2 infection and in different clinical conditions at the emergency department. The levels of the biochemical parameters at presentation in the emergency department were expected to vary strongly and therefore cannot be interpreted or be used as functional validation of the TIRAP polymorphism. Contrary to biochemical response, the genotypes are not influenced by the day of presentation of the SARS-CoV-2 infection. Consequently, the risk of confounded effect estimates is expected to be low.

ACE2 polymorphisms, including rs2285666, are associated with differences in gene expression and ACE2 receptor function [28, 29]. One third of our population was carrier of ACE2 polymorphism (rs2285666), with most patients being homozygous. This proportion was comparable with the allele frequency found in the general European population which is 20–23% [30]. We observed a lower occurrence of mortality, respiratory failure and venous thromboembolism, but whether this is a true signal is unclear as current data are not consistent [28, 29]. We found no carriers of the factor X polymorphism, which is concordant with the low allele frequency in the general population [31].

We acknowledge several limitations of the current study. First, the small sample size limits inference of associations in relevant subgroups due to low power. We chose only to include PCR confirmed patients with SARS-CoV-2, excluding any that may have been false negative. Only patients of Western European descent were included as genetic predisposition is different between races. Second, data collection was retrospective with no active follow-up of patients who were not hospitalised. We assumed that patients with clinical symptoms of respiratory failure or venous-thrombo-embolism would be re-admitted. Third, patients were included during the early phase of the COVID-19 pandemic. With advancing insights on treatment, such as dexamethasone and tocilizumab survival of patients has since improved [32]. Whether the investigated polymorphisms alter treatment effect of these drugs is not clear. All patients in this cohort had equal access to treatment options according to the then applicable Dutch national guidelines, which included oseltamivir (as influenza occurred during this period as well) and chloroquine.

In conclusion, this study shows that carriage of the TIRAP polymorphism rs8177374 could be associated with lower mortality in COVID-19. This TIRAP polymorphism may be an important predictor in the outcome of COVID-19 and external validation is necessary to consider this association. Further research should focus on exploration of interleukin-1, interleukin-6 and tumour necrosis factor alfa levels in relation to this TIRAP polymorphism and their association with clinical outcomes, and whether patients with carriage of this TIRAP polymorphism benefit more of specific treatments targeting the TIRAP pathway.

31 Aug 2021

PONE-D-21-24547

Association of genetic variations in ACE2, TIRAP, and factor X with outcomes in COVID-19.

PLOS ONE

Dear Dr. Traets,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 15 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kanhaiya Singh, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that outmoded terms and potentially stigmatizing labels should be changed to more current, acceptable terminology. Examples: “Caucasian” should be changed to “white” or “of [Western] European descent”.

3. Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.

Additional Editor Comments:

Although the reviewers have found this study interesting, they have suggested few experiments to make this study robust.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I suggest Author to cross validate the genotyping result with Sanger sequencing. Further It would be better to measure some biochemical parameters especially cytokines like Interleukins.

Why the author have taken plasma as a DNA source when it is possible to get intact genomic DNA from the whole blood. Plasma contains fragmented DNA and probability of having desired segment is less and thus it may hamper the genotyping result.

Reviewer #2: The research was done properly and it could be a basis for predicting clinical outcome based on the identified SNPs. It would be great if a figure can be included summarizing the genotype distribution along with the clinical outcome. For example, in Figure 3, the percentage of mortality can be included within the bar plot parts.

Reviewer #3: 1. Could the authors perform some functional validation of the TIRAP polymorphism, where population-specific TIRAP Single-Nucleotide Polymorphisms have limited impact on SARS-CoV-2 infectivity In Vitro?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Ahmed S Abouhashem

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

18 Oct 2021

We would like to thank the reviewers for a careful reading of our manuscript, and for the thoughtful comments. The constructive suggestions have helped to improve the manuscript’s quality. We have copied the reviewer’s comments below in italic. Our response and changes in the manuscript follow below the comments. Moreover, we have highlighted the changes in the revised manuscript accordingly. We hope that our response and the changes in the revised manuscript will be sufficient.

Reviewer 1

I suggest Author to cross validate the genotyping result with Sanger sequencing.

In our study real time Polymerase Chain Reactions (PCR) with specific primer pairs and probes were performed to determine the various alleles. Our PCR was successfully to determine the various alleles in 115 out of 116 patients, as explained in below. Therefore, we think there is no added value to cross validate the results with Sanger sequencing.

Further It would be better to measure some biochemical parameters especially cytokines like Interleukins.

We agree with the reviewer that measuring cytokines like interleukin-6 are of interest in patients with TIRAP polymorphism compared to patients with TIRAP wildtype. However, this study was designed to assess whether there is an association between the candidate genes (ACE2, TIRAP and Factor X) and the clinical course of SARS-CoV-2 infection. This study was not designed to determine an association between the candidate genes and biochemical parameters. The study population consists of patients who visited the emergency department with a clinical suspicion of SARS-CoV-2 infection. At that moment routinely blood was drawn of these patients. The patients presented at different days of onset of SARS-CoV-2 infection and in different clinical conditions. Therefore values of the biochemical parameters at presentation in the emergency department are expected to vary strongly. In addition, in particular levels of cytokines can increase exponentially. To detect any relevant differences, large sample sizes would be necessary. Interleukin-6 levels were not measured in our patients, so we cannot show this data. However, we did measure downstream inflammatory markers such as C-reactive protein, D-dimer and ferritin. C-reactive protein is a surrogate for the interleukin-6 pathway [1]. The results show a similar distribution between the two genotype groups at the moment of presentation at the emergency department. We added this table in the manuscript on page 12.

Table 3. Biochemical parameters in patients with TIRAP carriage and TIRAP wild-type

TIRAP

Carriage (N=28) Wild-type (N=87) P-value

C-reactive protein - mg/L 108 (47-187) 85 (42-168) 0.54

D-dimer - mg/L 1.1 (0.5-2.2) 1.3 (0.6-2.2) 0.63

Ferritin - µg/L 713 (370-1752) 776 (422-1573) 0.98

We added a sentence to the statistical analysis part of the article on page 8, line number 181-182: ‘The Mann-Whitney U test was performed to compare biochemical parameters between different genotypes.’

Furthermore we emphasized the results of the table in the manuscript on the results and discussion section on the following pages:

- Page 11, line number 227-229: ‘Table 3 shows levels of C-reactive protein, D-dimer and ferritin in patients with TIRAP carriage and TIRAP wild-type. Levels of these biochemical parameters show a similar distribution between the two genotype groups at the moment of presentation at the emergency department.’

- Page 13-14, line number 278-288: ‘However, we did measure downstream inflammatory markers such as C-reactive protein, D-dimer and ferritin. C-reactive protein is a surrogate for the interleukin-6 pathway [27]. The results show a similar distribution between patients with TIRAP carriage and TIRAP wild-type at the moment of presentation at the emergency department. However, this study was not designed to determine an association between the candidate genes and biochemical parameters. The patients in our study presented at different days of onset of SARS-CoV-2 infection and in different clinical conditions at the emergency department. The levels of the biochemical parameters at presentation in the emergency department were expected to vary strongly and therefore cannot be interpreted or be used as functional validation of the TIRAP polymorphism. Contrary to biochemical response, the genotypes are not influenced by the day of presentation of the SARS-CoV-2 infection. Consequently, the risk of confounded effect estimates is expected to be low.’

Why the author have taken plasma as a DNA source when it is possible to get intact genomic DNA from the whole blood. Plasma contains fragmented DNA and probability of having desired segment is less and thus it may hamper the genotyping result.

We agree with the reviewer that sequencing plasma can disturb the genotyping result because plasma contains fragmented DNA. However, our desired segments of the DNA were not fragmented in the plasma of our patients. Determination of TIRAP polymorphism of one patient could not be determined, possibly due to fragmented DNA of the desired segment. We have amplified the interested segments of the DNA of 115 out of 116 patients. If there was fragmented DNA of the desired segment, it would not be possible to amplify our DNA. In conclusion, real time polymerase chain reaction with using plasma as a DNA source was successfully to determine the various alleles in 115 out of 116 patients.

We emphasized this in the manuscript on page 11, line number 216-218: ‘Determination of the various alleles was successfully in 115 out of 116 patients. Determination of TIRAP polymorphism of one patient could not be determined due to technical issues.’

Reviewer 2

The research was done properly and it could be a basis for predicting clinical outcome based on the identified SNPs. It would be great if a figure can be included summarizing the genotype distribution along with the clinical outcome. For example, in Figure 3, the percentage of mortality can be included within the bar plot parts.

As suggested by the reviewer, we have made a figure summarizing the distribution of the outcome stratified per genotype. We agree with the reviewer that this visualization improves interpretation of the main findings of our study. No patients were carrier of Factor X polymorphism, and this was thus omitted from the figure. We added this figure in the manuscript on page 12.

Fig 4. Clinical outcomes stratified per genotype.

Reviewer 3

Could the authors perform some functional validation of the TIRAP polymorphism, where population-specific TIRAP Single-Nucleotide Polymorphisms have limited impact on SARS-CoV-2 infectivity In Vitro?

Our study was designed to assess whether there is an association between candidate genes (ACE2, TIRAP and Factor X) and clinical course of SARS-CoV-2 infection. Functional validation of the TIRAP polymorphism would contribute to the insights of mechanism. TIRAP has a function in the intracellular pro-inflammatory signalling pathway, and has no impact on SARS-CoV-2 receptor binding and cell entry of the virus as is known by ACE2, which is the receptor of the spike protein of SARS-CoV-2. We collected blood of patients at the moment of presentation at the emergency department. All patients in our study presented at different days of onset of SARS-CoV-2 infection and in different clinical conditions. The values of the biochemical parameters at presentation in the emergency department are expected to vary widely and therefore cannot be interpreted or be used as functional validation of the TIRAP polymorphism. Contrary to biochemical response, the genotypes are not influenced by the day of presentation of the SARS-CoV-2 infection. Consequently, the risk of confounded effect estimates is expected to be low. Future studies should collect interleukin-6 levels longitudinally during the course of a SARS-CoV-2 infection could add to understanding of the relation between carriage of the TIRAP polymorphism, different cytokine response and clinical outcomes in patients.

References

1. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998 Jan 15;128: 127-37. doi: 10.7326/0003-4819-128-2-199801150-00009.

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

19 Nov 2021

Association of genetic variations in ACE2, TIRAP, and factor X with outcomes in COVID-19.

PONE-D-21-24547R1

Dear Dr. Traets,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Kanhaiya Singh, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have addressed all the comments in satisfactory way. The manuscript can be accepted for the publication.

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #3: No

30 Dec 2021

PONE-D-21-24547R1

Association of genetic variations in ACE2, TIRAP and factor X with outcomes in COVID-19.

Dear Dr. Traets:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Kanhaiya Singh

Academic Editor

PLOS ONE

Table 1

ACE2 and TIRAP primers and probes sequences.

ACE2	Forward primer	5’–ATC TAT GTG TTG AAA CAC ACA TAT CTG C–3’
	Reverse primer	5’–AGA TAA TCC ACA AGA ATG CTT ATT ACT TGA–3’
	Probe C	5’ 6FAM–CAC TAC TAA AAA TTA GTA GCC TAC–3’
	Probe T	5’ VIC–CAC TAC TAA AAA TTA GTA GCT TAC CT–3’
TIRAP	Forward primer	5’–CTG CAG GCC CTG ACC G–3’
	Reverse primer	5’–AAT CGG AGC TCA GGT GGG TA–3’
	Probe C	5’ 6FAM–CTG CTG TCG GGC CT–3’
	Probe T	5’ VIC–CCC TGC TGT TGG GC–3’

Table 2

Baseline patient characteristics and outcomes.

				N = 116
Median age (IQR)—years				65	(55–75)
Female sex—no. (%)				41	(35.3)
Body-mass index—no. (%)*
	25–29 kg/m2			43	(37.1)
	≥ 30 kg/m2			24	(20.7)
Comorbidities—no. (%)
	Auto-immune or inflammatory disease			14	(12.1)
	Chronic obstructive pulmonary disease			16	(13.8)
	Diabetes Mellitus			17	(14.7)
	Coronary artery disease			19	(16.4)
	Hypertension			43	(37.1)
	Cancer			19	(16.4)
	History of venous thromboembolism			5	(4.3)
	History of ischemic stroke			6	(5.2)
Medication at baseline—no. (%)
	Immunosuppressive drugs
		Glucocorticoid		19	(16.4)
			Systemic	7	(6.0)
			Inhaled	15	(12.9)
		Other		4	(3.4)
	ACE inhibitor or ARB			28	(24.1)
	Antithrombotic drugs			31	(26.7)

*Body-mass index was available for 104/117 patients.

Abbreviations: IQR, inter quartile range; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.

Table 3

Genotype frequencies in survivors and non-survivors.

		Mortality				P-value
		Yes (N = 16)		No (N = 100)
ACE2	Carriage	4	(25.0%)	34	(34.0%)	0.58
	Wild-type	12	(75.0%)	66	(66.0%)
TIRAP	Carriage	0	(0.0%)	28	(28.0%)	0.01
	Wild-type	16	(100.0%)	71	(71.0%)
Factor X	Carriage	0	(0.0%)	0	(0.0%)	NA
	Wild-type	16	(100.0%)	100	(100.0%)

Table 4

Genotype frequencies in patients with and without respiratory failure.

		Respiratory failure
		Yes (N = 44)		No (N = 72)		P-value
ACE2	Carriage	12	(27.3%)	26	(36.1%)	0.42
	Wild-type	32	(72.7%)	46	(63.9%)
TIRAP	Carriage	7	(15.9%)	21	(29.2%)	0.12
	Wild-type	37	(84.1%)	50	(69.4%)
Factor X	Carriage	0	(0.0%)	0	(0.0%)	NA
	Wild-type	44	(100.0%)	72	(100.0%)

Table 5

Genotype frequencies in patients with and without venous thromboembolism.

		Venous thromboembolism
		Yes (N = 20)		No (N = 96)		P-value
ACE2	Carriage	4	(20.0%)	34	(35.4%)	0.20
	Wild-type	16	(80.0%)	62	(64.6%)
TIRAP	Carriage	4	(20.0%)	24	(25.0%)	0.78
	Wild-type	16	(80.0%)	71	(74.0%)
Factor X	Carriage	0	(0.0%)	0	(0.0%)	NA
	Wild-type	20	(100.0%)	96	(100.0%)

Data represent the number of patients (%) in each outcome group.

Abbreviation: NA, not applicable.

Table 6

Biochemical parameters in patients with TIRAP carriage and TIRAP wild-type.

	TIRAP
	Carriage (N = 28)	Wild-type (N = 87)	P-value
C-reactive protein—mg/L	108 (47–187)	85 (42–168)	0.54
D-dimer—mg/L	1.1 (0.5–2.2)	1.3 (0.6–2.2)	0.63
Ferritin - μg/L	713 (370–1752)	776 (422–1573)	0.98

Levels are depicted as median and 25th and 75th interquartiles.